Início › Leucemia Mieloide Aguda › Arizona
Ensaios clínicos de Leucemia Mieloide Aguda em Arizona
22 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Arizona.
Cidades em Arizona
Texto oficial do estudo (Inglês)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kingman Regional Medical Center, Kingman
- Cancer Center at Saint Joseph's, Phoenix
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Cancer Treatment Center of America Phoenix, Goodyear
- The University of Arizona Cancer Center, Tucson
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Mayo Clinic Hospital in Arizona, Phoenix
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05564390Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Clinical Trial Site, Goodyear
RecrutandoFase 3
Idades 12 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07211958Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Mayo Clinic Hospital in Arizona, Phoenix
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Banner Children's at Desert, Mesa
- Phoenix Childrens Hospital, Phoenix
- Banner University Medical Center - Tucson, Tucson
RecrutandoFase 3
6 Months – 21 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04293562(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Mayo Clinic Arizona, Phoenix
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT04996875Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Phoenix, Goodyear
- Mayo Clinic, Phoenix
- Honor Health, Scottsdale
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT04588922The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Banner Children's at Desert, Mesa
- Phoenix Childrens Hospital, Phoenix
- Banner University Medical Center - Tucson, Tucson
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Phoenix Children's Hospital, Phoenix
RecrutandoFase 3
29 Days – 21 Years · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Banner MD Anderson Cancer Center, Gilbert
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Banner MD Anderson Cancer Center, Gilbert
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT06001788A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Banner MD Anderson Cancer Center, Gilbert
- Phoenix Children's Hospital, Phoenix
- University of Arizona Medical Center - Tucson, Tucson
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT01351545Caris Chromoseq Data Collection
- Caris Life Sciences, Phoenix
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 2 de jul. de 2026 · NCT07680868A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Arizona, Scottsdale
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 10 de jun. de 2026 · NCT03017820Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Phoenix Children's Hospital, Phoenix
RecrutandoFase 1
Até 21 anos · Todos os sexos · Atualizado em 22 de abr. de 2026 · NCT05101551A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Mayo Clinic Arizona, Phoenix
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 13 de abr. de 2026 · NCT05732103Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
- Mayo Clinic in Arizona, Scottsdale
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 1 de abr. de 2026 · NCT06279572A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Mayo Clinic - Phoenix, Phoenix
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de mar. de 2026 · NCT05735184Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.